Stockreport

Zura Bio Reports Business Updates and Outlook for 2026

Zura Bio Limited - Class A Ordinary shares  (ZURA) 
PDF 2026 begins as a transformative year for Zura with potential clinical validation of tibulizumab as a groundbreaking therapy in hidradenitis suppurativa (HS)Expanded Phas [Read more]